Real-World Utilization and Discontinuation Patterns of Pcsk9 Inhibitor Use at a Large, Community-Based Lipid Clinic

Atul Chugh; Varun Dobariya; Christina Austin‐Tse; Kathleen Kioussopoulos; Vijay U. Rao; David Kovacich

doi:10.1016/s0735-1097(19)32387-3

March 1, 2019Journal of the American College of CardiologyOpen Access

Real-World Utilization and Discontinuation Patterns of Pcsk9 Inhibitor Use at a Large, Community-Based Lipid Clinic

View Full Paper

Ask AI

Bookmark

Share

Key result

Real-world cohort reveals PCSK9 inhibitor utilization, discontinuation rates, and payer patterns in clinical practice.

Key Points

To characterize real-world utilization, payer coverage patterns, and drug intolerance rates among patients prescribed PCSK9 inhibitors in a community-based lipid clinic.
Retrospective cohort analysis conducted at a cardiology-focused community lipid clinic.
Electronic health record queries for patients initiated on PCSK9 inhibitor therapy performed using the Epic SlicerDicer clinical analytics tool.
Payer coverage restrictions and prior authorization hurdles represent substantial practical barriers to initiating and maintaining PCSK9 inhibitor therapy.
Treatment discontinuation in clinical practice is primarily driven by insurance coverage denials and reported drug intolerance.

Structured PICO

P

Population

Patients at a cardiology-based community lipid clinic

I

Intervention

PCSK9 inhibitors

O

Outcome

Utilization, discontinuation patterns, payer origin, and intolerance rates

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational study observes PCSK9 inhibitor utilization and discontinuation in a community lipid clinic, highlighting real-world payer barriers and intolerance.

Abstract

PCSK9 inhibitor (PCSK9i) use continues to rise; however, access is limited. Herein, we describe our experience at a cardiology-based community lipid clinic with a focus on payer origin and intolerance rates. Queries for the clinic population on PCSK9i use were performed using the “Slicer-Dicer

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chugh et al. (2019) studied this question. PCSK9 inhibitor utilization and discontinuation patterns, including payer origin and intolerance rates, were characterized in a large community-based lipid clinic.

synapsesocial.com/papers/6a9cdb973cc8da7d0c4d6281 https://doi.org/10.1016/s0735-1097(19)32387-3

View Full Paper

Ask AI

Bookmark

Share

Real-World Utilization and Discontinuation Patterns of Pcsk9 Inhibitor Use at a Large, Community-Based Lipid Clinic

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Real-World Utilization and Discontinuation Patterns of Pcsk9 Inhibitor Use at a Large, Community-Based Lipid Clinic

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading